Impact clinique de l’arrêt de la corticothérapie chez des patients atteints de polyarthrite rhumatoïde traités par upadacitinib ou adalimumab

Autor: R. Fleischmann, B. Combe, A. Ostor, C. Pacheco Tena, N. Khan, J. Suboticki, A. Shmagel, Y. Song, G.I. Lagunes, G.R. Burmester

Publikováno v: Revue du Rhumatisme. 89:A170-A171

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::141539123d08c2e7651ed351d9756410
https://doi.org/10.1016/j.rhum.2022.10.252

POS0683 EFFICACY AND SAFETY OF UPADACITINIB IN TNFi-IR PATIENTS WITH RHEUMATOID ARTHRITIS FROM THREE PHASE 3 CLINICAL TRIALS

Autor: R. M. Fleischmann, L. Bessette, J. Sparks, S. Hall, M. Jain, A. Kakehasi, Y. Song, S. Meerwein, R. Demasi, J. Suboticki, A. Rubbert-Roth

Publikováno v: Annals of the Rheumatic Diseases. 81:618-619

BackgroundFor patients with RA who are refractory to biologic DMARDs (bDMARDs), such as tumor necrosis factor inhibitors (TNFis), optimal disease control is less likely to be achieved with subsequent therapy.1 In line with recommendations from EULAR

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::95e5b996954ebf96868ba0910af5ca6e
https://doi.org/10.1136/annrheumdis-2022-eular.1800

AB0352 IMPACT OF SEROLOGIC STATUS ON CLINICAL RESPONSES TO UPADACITINIB OR ABATACEPT IN PATIENTS WITH RHEUMATOID ARTHRITIS AND PRIOR INADEQUATE RESPONSE TO BIOLOGIC DMARDs: SUB-GROUP ANALYSIS FROM THE PHASE 3 SELECT-CHOICE STUDY

Autor: A. Rubbert-Roth, J. Sparks, A. Constantin, R. Xavier, Y. Song, J. Suboticki, R. M. Fleischmann

Publikováno v: Annals of the Rheumatic Diseases. 81:1302-1303

BackgroundIn patients with RA who had a prior inadequate response or intolerance to biologic DMARDs, the oral Janus kinase inhibitor, upadacitinib (UPA), demonstrated superiority in change from baseline in DAS28(CRP) and DAS28(CRP)ObjectivesTo evalua

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::1a85fa64be7f9dc0078961dedbd666c2
https://doi.org/10.1136/annrheumdis-2022-eular.2448

Patient-Reported Outcomes of Upadacitinib Versus Abatacept in Patients with Rheumatoid Arthritis and an Inadequate Response to Biologic Disease-Modifying Antirheumatic Drugs: 12-Week Results of a Phase 3 Trial

Autor: J. Suboticki, Namita Tundia, Naomi Martin, Martin J. Bergman, Debbie Goldschmidt, Grace C. Wright, Yan Song

Background In previous clinical trials, patients with active rheumatoid arthritis (RA) treated with upadacitinib (UPA) have improved patient-reported outcomes (PROs). This post hoc analysis of SELECT-CHOICE, a phase 3, double-blind, randomized clinic

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::e1c4415161dd04c9375dda0c3a6110de
https://doi.org/10.21203/rs.3.rs-734225/v1

Upadacitinib monotherapy improves patient-reported outcomes in rheumatoid arthritis:results from SELECT-EARLY and SELECT-MONOTHERAPY

Autor: Martin J. Bergman, Maya H Buch, Alan Friedman, Heidi S. Camp, Debbie Goldschmidt, J. Suboticki, Namita Tundia, K. Dunlap, Vibeke Strand, Alvin F. Wells, Sebastião Cezar Radominski

Publikováno v: Strand, V, Tundia, N, Wells, A, Buch, M H, Radominski, S C, Camp, H S, Friedman, A, Suboticki, J L, Dunlap, K, Goldschmidt, D & Bergman, M 2020, ' Upadacitinib monotherapy improves patient-reported outcomes in rheumatoid arthritis : results from SELECT-EARLY and SELECT-MONOTHERAPY ', Rheumatology (Oxford, England) . https://doi.org/10.1093/rheumatology/keaa770
Rheumatology (Oxford, England)

Objective To evaluate the effect of upadacitinib (UPA) monotherapy vs MTX on patient-reported outcomes (PROs) in patients with RA who were MTX-naïve or who had an inadequate response to MTX (MTX-IR). Methods PROs from the SELECT-EARLY and SELECT-MON

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::95b5798905abbf84b6b50a9a64da535c
https://www.research.manchester.ac.uk/portal/en/publications/upadacitinib-monotherapy-improves-patientreported-outcomes-in-rheumatoid-arthritis(089c4705-7e6c-4c8f-b706-e56d80a1b482).html